pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,593 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT814Endpoints614BioPharma Dive237onclive165Fierce Biotech82BioSpace80raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • STAT+: Trump administration seeks to overhaul federal grantmaking process, alarming researchers
    The Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants.
    STAT · 2mo ago↗ source
  • Next FDA user fee deal is under review at the White House
    The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sour…
    Endpoints · 2mo ago↗ source
  • Post-Hoc: Lilly gets more secretive and hides Phase 1 pipeline
    Eli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings pres…
← prev
page 37 of 64
next →
21
fda recalls20
fda medwatch16
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 2mo ago
↗ source
  • AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
    🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…
    Endpoints · 2mo ago↗ source
  • Replimune will again submit its melanoma drug for approval
    Third time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...
    Endpoints · 2mo ago↗ source
  • Kenya court suspends U.S. plan for Ebola quarantine facility for Americans
    A court in Kenya on Friday suspended a U.S. plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus spreading in northeastern Congo.
    STAT · 2mo ago↗ source
  • Agios ends development of tebapivat in low-risk MDS following subpar results
    Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruv…
    Endpoints · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
    Pharma updates from the Pharmalot campus via the Pharmalittle newsletter
    STAT · 2mo ago↗ source
  • STAT+: Allogene CEO David Chang stepping down
    Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The Readout
    STAT · 2mo ago↗ source
  • STAT+: Massachusetts sues UnitedHealth, alleging fraud in state’s Medicaid plans for seniors
    State AG alleges UnitedHealthcare claimed some members were sicker to boost its profits.
    STAT · 2mo ago↗ source
  • Which vaccines will curb the Ebola outbreak? WHO debates
    The growing Ebola outbreak, the unknowns of microdosing GLP-1s, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 2mo ago↗ source
  • #ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successor
    Bristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen. The New Jersey p…
    Endpoints · 2mo ago↗ source
  • David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow
    Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by ...
    Endpoints · 2mo ago↗ source
  • Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
    On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific anti…
    Endpoints · 2mo ago↗ source
  • STAT+: The woman behind the world’s biggest longevity competition
    Jamie Justice of XPRIZE Healthspan on the most promising research and "purely scammy" treatments in the world of longevity.
    STAT · 2mo ago↗ source
  • Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
    Long term, we don’t know what tiny doses of GLP-1s for cosmetic weight loss can do, writes a weight-loss doctor.
    STAT · 2mo ago↗ source
  • STAT+: As Ebola outbreak in Central Africa grows, the U.S. turns itself into a fortress
    The U.S. is taking extraordinary steps to keep Ebola out. But its policies may create risks for Americans infected overseas and discourage volunteers from responding to the outbreak.
    STAT · 2mo ago↗ source
  • Lilly obesity meds Foundayo and Zepbound to gain CVS coverage
    Eli Lilly’s flagship obesity medications will be included in CVS Caremark formularies, likely boosting sales in the most competitive commercial drug market. The company announced Thursday that its…
    Endpoints · 2mo ago↗ source
  • For wearables, it’s a GLP-1 world
    We have two pieces of wearables-related news for you today, and (maybe unsurprisingly) GLP-1s came up in our conversations with both companies. First, Signos raised $20 million for its approach ...
    Endpoints · 2mo ago↗ source
  • ICON audit finds overstated revenue; Secretome and Psilera raise cash
    👀 ICON’s audit probe is complete: The investigation found that ICON’s revenue was overstated by $65.3 million in 2023 (about 0.8% of its total revenue that year) and by $92.7 million in 2024 (1.1%…
    Endpoints · 2mo ago↗ source
  • #ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project
    In 2022, Frank Fan moved more than 800 miles from Nanjing to Shenzhen, China, seeking a fresh start. He had abruptly left Legend Biotech, the CAR-T company he co-founded, just one month after the m…
    Endpoints · 2mo ago↗ source
  • Niowave’s $75M radioisotope facility; CordenPharma to buy AmbioPharm
    Plus, news about Agilent’s earnings report: ☢️ Niowave’s radioisotope factory: The company has broken ground on a $75 million production facility in Lansing, MI, which will be used to manufacture a…
    Endpoints · 2mo ago↗ source
  • Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
    Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies…
    Endpoints · 2mo ago↗ source
  • China gene editing startup YolTech raises $70M to move CRISPR therapies forward
    One of China’s most prolific gene editing companies has raised its biggest round of funding yet, ahead of plans to go public in Hong Kong. While most gene editing companies in the US trimmed their ...
    Endpoints · 2mo ago↗ source